Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.

Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T

DOI: 10.1067/mcp.2000.106932
Published: 2000 Jun
Container: Clinical pharmacology and therapeutics
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1067/mcp.2000.106932,
  title = {Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.},
  author = {Zylber-Katz E and Gomori JM and Schwartz A and Lossos A and Bokstein F and Siegal T},
  year = {2000},
  journal = {Clinical pharmacology and therapeutics},
  doi = {10.1067/mcp.2000.106932},
  url = {https://doi.org/10.1067/mcp.2000.106932}
}

RIS

TY  - JOUR
TI  - Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
AU  - Zylber-Katz E
AU  - Gomori JM
AU  - Schwartz A
AU  - Lossos A
AU  - Bokstein F
AU  - Siegal T
PY  - 2000
JO  - Clinical pharmacology and therapeutics
DO  - 10.1067/mcp.2000.106932
UR  - https://doi.org/10.1067/mcp.2000.106932
ER  -

APA

E, Z., JM, G., A, S., A, L., F, B., & T, S. (2000). Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.. Clinical pharmacology and therapeutics. https://doi.org/10.1067/mcp.2000.106932

Source records

pubmed · retrieved 2026-09-24T23:23:20.114Z
europe-pmc · retrieved 2026-09-24T23:23:20.107Z